Kiersten Archer

Director

Washington

Kiersten Archer is a Director within Controls Risks’ Compliance, Forensics and Intelligence practice in the Americas region. She has significant experience in corporate compliance, fraud and anti-corruption matters.

  • Americas
  • Corruption Risk Assessment & Analysis
  • Cross Border Investigations
  • Government-Mandated Monitorships


Kiersten Archer is a Director within Controls Risks’ Compliance, Forensics and Intelligence practice in the Americas region. She has significant experience in corporate compliance, fraud and anti-corruption matters.

Kiersten specializes in bribery and fraud investigations, compliance risk assessments and development of best-practice anti-corruption compliance programs. Her experience in matters involving violations of the US Foreign Corrupt Practices Act (FCPA) and the UK Bribery Act includes global financial and forensic accounting investigations with suspected violations by US corporations or their international operating divisions, agents or distributors. She has also worked on global risk assessments, SEC and DOJ enforcement-driven investigations, and monitorships in numerous global jurisdictions.


Kiersten’s recent experience includes:
  • Participation in global on-site anti-corruption investigations and risk assessments for medical devices, pharmaceutical and dental implant companies, including focused transactional testing and data analytics to determine FCPA corruption risk.
  • Assisted clients with global compliance program gap analyses and remediation, including development of corruption risk profiles.
  • In a large financial institution securities litigation matter, assisted in responding to allegations that senior management issued materially false and misleading financial reports, artificially inflating the price of the entity’s securities.
  • Participated in a complex independent investigation into a leading pharmaceutical company’s operations and interactions with healthcare professionals, distributors and vendors in China.Played a key role on a court-appointed independent compliance consulting team for a large global pharmaceutical company in connection with an FCPA settlement with the SEC.


Prior to joining Control Risks, Kiersten spent a decade at FTI Consulting where she was a senior director in its forensic and litigation consulting practice focusing on anti-corruption compliance and investigations.

FIND OUT MORE

Can our experts help you?

Related content

RiskMap 2018

The flag and the republic

Think about the US as two countries: one is the global superpower, with its indispensable diplomacy, military deployments, cultural dominance, and dense trade and financial relations; the other is the local republic, mostly consumed by daily life, where jobs, health, family and heritage...

RiskMap 2018

Latin America: promise from afar

From a distance, Latin America shows a tempting array of positive indicators. In most of the region’s economies, the painful slowdown triggered by the 2014 collapse in commodity prices has largely ended. Economic growth across the continent is expected to expand from ...

Analysis

Natural disasters and the challenge of business resumption

Over the past month, severe weather has wreaked havoc across the Gulf Coast of the United States, the Caribbean and South Eastern US. As a result of the hurricanes and tropical storms, businesses across the impacted regions have shuttered operations while employees struggle to care for their families and property.

Analysis

Automotive brief: North America

Preparations are continuing for the formal start of talks between the US, Canada and Mexico over a renegotiation of the terms of the North American Free Trade Agreement (NAFTA), after US President Donald Trump’s 18 May announcement that he wished to seek a new deal triggered a 90-day countdown for talks to begin.

Analysis

Trump expectations

In an interview with the Associated Press on 21 April, US president Donald Trump downplayed the significance of his ‘first 100 days’ in office: “I've done more than any other president in the first 100 days and I think the first 100 days is an artificial barrier.”